(917) 310-3371
Order and treatment record
Bring or send the signed order, diagnosis, intended dose, last injection or oral dose, next due date, initiation history, and prescriber contact details.
Invega Hafyera injection care in NYC
Psychiatry-led evaluation, accepted outside-order coordination, patient-specific delivery, administration, and monitoring for Invega Hafyera.
Invega Hafyera is a six-month paliperidone palmitate injection for adults with schizophrenia who are already adequately treated with a monthly or three-month paliperidone injection. Nao Medical can coordinate an accepted outside order, patient-specific delivery, administration, visit monitoring, and ongoing psychiatry. Stabilization records, renal review, coverage, medication arrival, and the eligible clinic must be confirmed first.
Records first, appointment second
A complete handoff helps prevent an incorrect dose, an avoidable delay, or a visit at the wrong clinic.
What to know about Invega Hafyera
Paliperidone palmitate six-month intramuscular injection. The current label describes treatment of schizophrenia in adults after adequate treatment with monthly paliperidone palmitate for at least four months or one three-month paliperidone palmitate cycle.
Approved use
treatment of schizophrenia in adults after adequate treatment with monthly paliperidone palmitate for at least four months or one three-month paliperidone palmitate cycle
Schedule
once every six months
Administration route
intramuscular injection in the gluteal muscle only
Responsible prescriber
A named psychiatric prescriber remains responsible for the regimen, dose, and any medication change.
A clear clinical and operational handoff
When clinically appropriate, Nao Medical can evaluate the request and coordinate ongoing psychiatry. If an outside psychiatric clinician sends a valid order and adequate records, Nao reviews whether the order can be accepted, coordinates patient-specific medication delivery, confirms an eligible administration clinic, administers the injection, and monitors the visit. Acceptance is not automatic, and Nao does not change the medication or dose without a valid prescriber-led plan.
The medicine is coordinated for the individual patient. An evaluation does not guarantee eligibility, order acceptance, medication access, or administration at the clinic where the evaluation occurs.
Initiation, schedule, and late-dose planning
Before the first dose
Invega Hafyera is not a first paliperidone injection. The label requires adequate treatment with monthly paliperidone palmitate for at least four months or with one three-month paliperidone palmitate cycle. The responsible prescriber confirms the stabilization history and selects the corresponding six-month dose.
Labeled schedule and route
Invega Hafyera is given once every six months by intramuscular injection in the gluteal muscle only.
If a dose is late
The label allows a limited dosing window around the six-month date. A longer gap requires re-initiation with monthly paliperidone injections, with the number of doses based on how late the injection is. Exact dates must be reviewed before scheduling.
No automatic medication change
A long-acting injection cannot simply be removed. Any change requires a prescriber-led plan that accounts for the prior dose and the next product's initiation rules.
What to prepare before scheduling
A complete record lets the clinical and operations teams confirm the right medicine, timing, delivery path, and clinic before the visit.
Medication and safety record
Include current medicines, allergies, prior adverse effects, pregnancy or breastfeeding considerations, recent hospitalization records, and relevant laboratory or monitoring results.
Coverage and delivery details
Share insurance cards, the specialty pharmacy or distributor if known, prior authorization status, and the intended patient-specific delivery destination.
Timing confirmation
Wait for the care team to confirm order acceptance, medication arrival, the eligible clinic, trained staff, and appointment time before traveling.
Safety and monitoring
Review renal function, symptoms, movement effects, prolactin-related effects, weight, glucose, lipids, blood pressure, sedation, interacting medicines, pregnancy considerations, and gluteal injection-site effects.
Upper respiratory infection, injection-site reactions, weight increase, headache, and parkinsonism are among the common reactions described in the prescribing information.
All eight labels carry a boxed warning about increased mortality in older adults with dementia-related psychosis and state that the product is not approved for that use. Other important risks can include neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, low blood pressure or falls, low white blood cell counts, seizures, swallowing problems, impaired temperature regulation, and cognitive or motor impairment. The full product label and the patient's history control the care plan.
When to get urgent help
Get emergency help for trouble breathing or facial swelling, fainting, very high fever with severe muscle stiffness or confusion, a seizure, or a sudden major change in consciousness. Contact the psychiatric prescriber promptly for new uncontrolled movements, severe restlessness, marked sedation, rapidly worsening symptoms, or thoughts of self-harm. Call 911 or 988 when immediate safety is at risk.
Coverage and medication access
The office visit, the medication, and administration may process through different parts of an insurance plan. Prior authorization, specialty-pharmacy requirements, patient-specific shipment, and manufacturer-program eligibility vary. Nao confirms the acquisition path and medication arrival before the administration appointment; no payment or coverage result is guaranteed.
Benefits review
Coverage is checked against the intended diagnosis, product, dose, benefit channel, and administration setting.
Patient-specific delivery
The order and delivery destination are coordinated before the visit. Patients should not transport medication unless the care team gives explicit instructions.
Manufacturer support
J&J withMe savings and support may provide access information under its current terms. Eligibility and services can change.
Ongoing psychiatry
Follow-up remains necessary to assess benefit, side effects, laboratory or physical monitoring, symptoms before the next dose, and whether the plan should continue.
Evaluation and coordination locations across New York
The clinics below can serve as nearby access points for an initial medical evaluation, records coordination, or follow-up planning. They are not a list of confirmed administration sites for every medication. The care team will confirm the correct clinic after reviewing the order, delivery path, staffing, and visit timing.
Bronx
174th Street
932 E 174th St, Bronx, NY 10460
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in West Farms, Crotona Park East, and nearby Bronx neighborhoods. The administration clinic will be confirmed separately by the care team.
Queens
Astoria
37-15 23rd Ave, Astoria, NY 11105
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in Astoria, Ditmars, East Elmhurst, and nearby Queens neighborhoods. The administration clinic will be confirmed separately by the care team.
Bronx
Bartow Mall
2063A Bartow Ave, Bronx, NY 10475
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in Co-op City, Pelham Bay, Baychester, and nearby Bronx neighborhoods. The administration clinic will be confirmed separately by the care team.
Brooklyn
Crown Heights
341 Eastern Pkwy, Brooklyn, NY 11216
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in Crown Heights, Prospect Heights, and nearby Brooklyn neighborhoods. The administration clinic will be confirmed separately by the care team.
Long Island
Hicksville
232 W Old Country Rd, Hicksville, NY 11801
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in Hicksville, Plainview, Bethpage, and nearby Nassau County communities. The administration clinic will be confirmed separately by the care team.
Queens
Jackson Heights
80-10 Northern Blvd, Jackson Heights, NY 11372
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in Jackson Heights, Elmhurst, Corona, and nearby Queens neighborhoods. The administration clinic will be confirmed separately by the care team.
Queens
Jamaica
90-18 Sutphin Blvd, Jamaica, NY 11435
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in Jamaica, Briarwood, Richmond Hill, and nearby Queens neighborhoods. The administration clinic will be confirmed separately by the care team.
Queens
Long Island City
30-07 36th Ave, Astoria, NY 11106
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in Long Island City, Astoria, Sunnyside, and nearby Queens neighborhoods. The administration clinic will be confirmed separately by the care team.
Long Island
Mineola
135 Mineola Blvd, Mineola, NY 11501
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in Mineola, Garden City, Westbury, and nearby Nassau County communities. The administration clinic will be confirmed separately by the care team.
Manhattan
StuyTown
259 1st Ave, New York, NY 10003
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in StuyTown, East Village, Gramercy, and nearby Manhattan neighborhoods. The administration clinic will be confirmed separately by the care team.
Brooklyn
Williamsburg
308 Graham Ave, Brooklyn, NY 11211
A nearby Nao Medical access point for evaluation, records coordination, and follow-up planning for patients in Williamsburg, Greenpoint, Bushwick, and nearby Brooklyn neighborhoods. The administration clinic will be confirmed separately by the care team.
Questions about Invega Hafyera
Nao can review a valid outside order and supporting records. The responsible prescriber must remain clear, and Nao must accept the order, coordinate patient-specific delivery, confirm an eligible clinic and trained staff, and schedule the visit before administration.
The current U.S. prescribing information lists treatment of schizophrenia in adults after adequate treatment with monthly paliperidone palmitate for at least four months or one three-month paliperidone palmitate cycle. A diagnosis alone does not establish that the medicine is appropriate for a particular person.
The labeled schedule is once every six months. It is given by intramuscular injection in the gluteal muscle only. The prescribed dose, timing, and administration instructions must be confirmed from the current order and treatment record.
Invega Hafyera is not a first paliperidone injection. The label requires adequate treatment with monthly paliperidone palmitate for at least four months or with one three-month paliperidone palmitate cycle. The responsible prescriber confirms the stabilization history and selects the corresponding six-month dose.
The label allows a limited dosing window around the six-month date. A longer gap requires re-initiation with monthly paliperidone injections, with the number of doses based on how late the injection is. Exact dates must be reviewed before scheduling.
Nao does not make an automatic medication switch. The responsible psychiatric prescriber must review diagnosis, response, side effects, prior doses, current symptoms, interactions, and the new product's initiation rules, then issue a valid plan and order when appropriate.
Review renal function, symptoms, movement effects, prolactin-related effects, weight, glucose, lipids, blood pressure, sedation, interacting medicines, pregnancy considerations, and gluteal injection-site effects.
Invega Hafyera was not listed in FDA's active REMS database when checked on August 1, 2026. That does not remove its boxed warning, prescribing-information requirements, or the clinic's responsibility to verify delivery, storage, administration, monitoring, and emergency procedures.
Coverage varies by plan, diagnosis, benefit channel, prior authorization, pharmacy network, and administration site. Nao can coordinate a benefits review after the clinical plan and intended delivery path are clear. Manufacturer programs have separate eligibility rules and do not promise coverage.
Official sources and safety information
The full current prescribing information controls. FDA's active REMS list did not include Invega Hafyera when checked on August 1, 2026; the label and clinic safety procedures still apply.
- DailyMed: current Invega Hafyera prescribing information
- FDA: current active REMS database
- J&J withMe savings and support
- FDA MedWatch: report a suspected medication problem
Official sources checked August 1, 2026. The DailyMed label shown above has an effective date of 2025-02-18 and identifies prescribing-information revision 01/2025. Questions or corrections about this medical information can be sent to service@naomedical.com.
Health information notice
General information only. This page is not medical advice and does not replace diagnosis, treatment, or guidance from a licensed clinician.
Content was updated August 1, 2026 from the sources cited on this page. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.